Further Information
Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase, Core 2-branching enzyme, Core2-GlcNAc-transferase, C2GNT, Core 2 GNT, GCNT1, NACGT2
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
Glycosylation is one of the most universal but at the same time complex protein modifications. Modification with sugar moeties can be both co- translational and post- translational, occurring in the endoplasmatic reticulum and golgi. Three different forms of glycosylation can be distinguished: N-linked oligosaccharides, O-linked oligosaccharides and glycosyl- phosphatidylinositol (GPI-) anchors. Glycosylation results in thousands of distinct, bioactive glycoproteins resident throughout the cell that strongly determine protein-protein, carbohydrate-protein, membrane, and adhesion properties. Diseases associated with glycosylation defects include Congenital disorders of glycosylation, (CDG), also known as carbohydrate deficient glycoprotein syndromes, and diseases associated with advanced aging.
- Bierhuizen, M.F., et al., Glycobiology 5(4):417-425 (1995).
- Bierhuizen, M.F., et al., Proc. Natl. Acad. Sci. U.S.A. 89(19):9326-9330 (1992).
Supplied in PBS with 0.09% (W/V) sodium azide.
batch dependent
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
This GCNT1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 399-428 amino acids from the C-terminal region of human GCNT1.
2650
Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase
GCNT1
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
50 kDa
Q02742
218512053
This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Obesity,Signal Transduction
Q02742
Optimal dilutions for each application to be determined by the researcher.